Telo Genomics announced that its proprietary blood-based TELO-MRD assay detected residual multiple myeloma cells in 92.9% of matched samples, outperforming the standard bone marrow EuroFlow next-generation flow cytometry which detected 54.8%. The TELO-MRD test not only counts residual cancer cells but also profiles their genomic instability, potentially offering better relapse risk assessment. The company plans to further develop and commercialize this non-invasive test by the end of 2027, aiming to improve personalized treatment for multiple myeloma patients.
Telo Genomics clinical research results provide context for readers. For those following the health sector, 35 of 91 US health stocks rose and 48 fell on Pluang. ENVB was priced at USD 1.46 with a -2.67% change, INO at USD 1.21 with +2.54%, and ABCL at USD 11.00 with -1.52%, as of Sep 15, 2026 16:41 WIB.
Kering has released its monthly statement detailing the total number of shares and voting rights as of October 15, 2026. The company reported 123,420,778 total shares and 176,815,752 theoretical voting rights, with 176,046,302 exercisable voting righ...
Kering published its monthly update on October 15, 2026, reporting a total of 123,420,778 shares composing its capital and 176,815,752 theoretical voting rights. The voting rights figure includes all shares with voting rights, including those tempora...
Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
